CCA
MRTX

Column Capital Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Column Capital Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-216
Closed -$47K – 749
2020
Q4 		$47K Sell
216
-489
-69% -$106K 0.01% 284
2020
Q3 		$117K Sell
705
-368
-34% -$50.4K 0.04% 145
2020
Q2 		$122K Hold
1,073
– – 0.04% 132
2020
Q1 		$82K Buy
1,073
+231
+27% +$20.7K 0.03% 140
2019
Q4 		$108K Buy
+842
New +$81.2K 0.05% 139

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Column Capital Advisors's MRTX Position: Q1 2021 in Review

Column Capital Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2021, closing a stake of 216 shares — an estimated $47K sold.

Column Capital Advisors first reported a position in MRTX in Q4 2019 and held it in 5 quarters. The position peaked at $122K in Q2 2020. 260 funds tracked by Wall St. Rank hold MRTX as of Q1 2021.

  • Column Capital Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Column Capital Advisors sold 216 Mirati Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $47K.
  • Column Capital Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2019 and held it in 5 quarters.
  • Column Capital Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $122K in Q2 2020.
  • 260 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Column Capital Advisors's 13F filing for Q1 2021, filed 10 May 2021.